Pick up almost any branded T-shirt, pair of jeans or running shoe and there is a fair chance that the thread keeping it in one piece came from Coats Group. The London-listed group, with roots stretching back over 250 years, calls itself as the world's leading "tier 2" supplier to the apparel and footwear industries. It sells essential components to the factories that sew garments. By its own estimates, Coats held roughly 27% of the premium apparel thread market in 2025, up from about 26% a year earlier.

Thread is a tiny fraction of a garment's cost but a big risk if it fails, since a broken seam costs far more than the thread saved. That gives Coats pricing power and sticky relationships with more than 25,000 customers and 1,300 Brand partners. Over the past year it has used that base for its biggest bet in years, buying premium insole maker OrthoLite and reshaping itself into Apparel and Footwear divisions.

How the Business makes money

Coats reports in US dollars and employs about 19,000 people in more than 50 countries, supplying factories close to the garment and shoe hubs that global brands rely on.

The Apparel division sells premium industrial sewing threads, plus zips, trims and related products. The Footwear division supplies threads and structural components such as toe caps and heel counters, and, since October 2025, OrthoLite's open-cell foam insoles. OrthoLite claims about 36% of its niche, ships over 500 million pairs a year to around 550 brands, and has more than 310 co-branding agreements. The former Performance Materials unit was folded into these two divisions in 2026.

Sustainability is a real Revenue driver: recycled thread sales reached $554m in 2025, up 43% at constant exchange rates.

Recent performance

In the year to 31 December 2025, Coats (LSE:COA) grew revenue 2% on a reported basis to $1,465m. On an organic, constant-currency basis sales were flat, which management contrasted with core markets that it estimates fell by a low-to-mid single-digit percentage. Adjusted operating profit (EBIT) rose to $290m, and the Margin widened by 80 basis points to 19.8%. Free Cash Flow hit a record $160m (2024: $2m). Adjusted EPS slipped to 9.3 cents from 9.7 cents, with the share count enlarged by the OrthoLite placing. The full-year Dividend rose 5% to 3.28 cents.

In the six months to 30 June 2026, revenue rose 19% to $837m, but organic growth was only 1%. Adjusted EBIT rose 19% to $166m, with the margin held at 19.8%, though it fell 2% on an organic basis. Adjusted EPS dropped 6% to 4.4 cents, free cash flow was $30m, and net Debt (excluding leases) was $842m, or 2.3 times EBITDA. The Interim Dividend was lifted 5% to 1.05 cents. Apparel grew 1% organically, well ahead of a shrinking thread market, while Footwear was flat, partly held back by OrthoLite capacity problems in Indonesia. The shares rose about 9% on results day.

Strategy and catalysts

The OrthoLite deal, completed at the end of October 2025, carried a $770m enterprise value: 10 times standalone EBITDA, or under 8 times once $20m of annual cost synergies arrive by 2028. It was funded with new debt and a placing of about 320 million shares at 77p, raising roughly £246m. Management also targets at least $40m of extra annual revenue from cross-selling by 2030, and Coats' Pleret factory in Indonesia should start making OrthoLite insoles in early 2027, easing the capacity squeeze.

In March 2026 the company raised its medium-term targets. It now aims for average revenue growth above 5% through the cycle, EBIT margins of 21% to 23% (previously 19% to 21%), EPS growth above 10% a year, and around $1bn of cumulative free cash flow over five years. Catalysts include new OrthoLite products, such as premium running foams and safety-footwear insoles, with first sales expected in the second half of 2026. Smaller "target adjacencies", from oil-and-gas tape to fire-service PPE technology and Coats Digital software, added around 1% to first-half growth.

Tim Cobbold became chair on 1 August 2026, succeeding David Gosnell after 11 years; David Paja remains chief executive.

Valuation talking points

The key debate is whether Coats deserves a higher rating as a specialised component supplier or remains a cyclical textile play. The OrthoLite price looks reasonable after synergies, but dilution explains why adjusted EPS fell in 2025 and again in the first half of 2026 despite record dollar profits. Management expects good Earnings growth for 2026 as a whole, helped by around $15m of cost savings in the second half. Its capital-allocation priority is to cut Leverage to 2.0 times or below by the end of 2026. After that, surplus cash could fund Buybacks or bolt-on deals, alongside a progressive dividend.

The bull case

  • Coats is gaining share in a shrinking market, which suggests its pricing power and customer relationships are real, not just cyclical.
  • OrthoLite gives it a high-margin, brand-facing footwear franchise, with cost and revenue synergies still to come.
  • The raised 21% to 23% margin target, if met, would mark a clear step up from the 19.8% achieved in 2025.
  • Strong cash generation, with around $1bn targeted over five years, could fund deleveraging, dividends and buybacks.

The bear case

  • Core apparel and footwear markets were estimated to be down mid-single digits in the first half of 2026, and a recovery has no clear timeline.
  • US Tariff uncertainty and conflict in the Middle East create Volatility in orders and input costs.
  • Leverage of 2.3 times at June 2026 limits flexibility until deleveraging is done.
  • OrthoLite's Indonesian capacity issues show the integration risk, and a large share of profit now rests on one Acquisition delivering.
  • Adjusted EPS has fallen for two consecutive reporting periods because of the enlarged share count.

The bottom line

Coats' thread really does hold much of the world's clothing together, and its rising share of a weak market shows the strength of that position. The past year turned a thread specialist into a broader apparel and footwear components group, with ambitious targets attached.

What happens next depends on execution: fixing OrthoLite's capacity, delivering synergies, cutting leverage to 2.0 times and, above all, returning to per-share earnings growth. If end markets recover as those pieces fall into place, the business could look very different in a few years; if not, patience will be required.